Login
Home
Charts
Search
Watchlist
Products

Vikram Thermo (India) Ltd

VIKRAMTH·BSE
382.95+16.91%Tue, 22 Sept '26 15:22

Vikram Thermo (India) Ltd

VIKRAMTH
BSE
382.95
+16.91%
|Tue, 22 Sept '26 15:22
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,204Cr
Close
Close Price
384.00
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
27.45
PS
Price To Sales
8.34
Revenue
Revenue
144Cr
Rev Gr TTM
Revenue Growth TTM
16.66%
PAT Gr TTM
PAT Growth TTM
42.25%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
342427313434272935343838
Growth YoY
Revenue Growth YoY%
16.6-9.9-9.643.5-0.540.9-1.0-8.22.9-0.939.332.4
Expenses
ExpensesCr
221520202121201719192620
Operating Profit
Operating ProfitCr
129812121371115151218
OPM
OPM%
35.738.727.437.137.138.924.639.544.744.531.747.6
Other Income
Other IncomeCr
000-231-1100011
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111111111
PBT
PBTCr
1197-13131271115151218
Tax
TaxCr
321323334445
PAT
PATCr
865-16109481111913
Growth YoY
PAT Growth YoY%
56.395.226.1-374.818.740.1-17.4150.213.221.5109.367.3
NPM
NPM%
24.426.418.0-50.829.126.315.027.832.032.222.635.1
EPS
EPS
2.62.01.6-5.03.13.21.32.53.53.52.74.2
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
342427313434272935343838
Growth YoY
Revenue Growth YoY%
16.6-9.9-9.643.5-0.540.9-1.0-8.22.9-0.939.332.4
Expenses
ExpensesCr
221520202121201719192620
Operating Profit
Operating ProfitCr
129812121371115151218
OPM
OPM%
35.738.727.437.137.138.924.639.544.744.531.747.6
Other Income
Other IncomeCr
000-231-1100011
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111111111
PBT
PBTCr
1197-13131271115151218
Tax
TaxCr
321323334445
PAT
PATCr
865-16109481111913
Growth YoY
PAT Growth YoY%
56.395.226.1-374.818.740.1-17.4150.213.221.5109.367.3
NPM
NPM%
24.426.418.0-50.829.126.315.027.832.032.222.635.1
EPS
EPS
2.62.01.6-5.03.13.21.32.53.53.52.74.2

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
38454958567493112101126134144
Growth
Revenue Growth%
3.317.78.418.8-4.131.825.820.5-9.224.66.216.7
Expenses
ExpensesCr
313744494456788564828084
Operating Profit
Operating ProfitCr
88591218152637455461
OPM
OPM%
20.018.710.415.421.224.615.923.436.735.440.342.0
Other Income
Other IncomeCr
000000111323
Interest Expense
Interest ExpenseCr
001111111100
Depreciation
DepreciationCr
112222332333
PBT
PBTCr
6736916122335445259
Tax
TaxCr
231224369101416
PAT
PATCr
452471291726343944
Growth
PAT Growth%
36.110.9-50.288.963.466.7-28.094.654.129.614.042.3
NPM
NPM%
11.010.44.87.613.016.49.415.225.726.728.730.4
EPS
EPS
1.51.70.81.62.43.92.85.48.12.612.314.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
38454958567493112101126134144
Growth
Revenue Growth%
3.317.78.418.8-4.131.825.820.5-9.224.66.216.7
Expenses
ExpensesCr
313744494456788564828084
Operating Profit
Operating ProfitCr
88591218152637455461
OPM
OPM%
20.018.710.415.421.224.615.923.436.735.440.342.0
Other Income
Other IncomeCr
000000111323
Interest Expense
Interest ExpenseCr
001111111100
Depreciation
DepreciationCr
112222332333
PBT
PBTCr
6736916122335445259
Tax
TaxCr
231224369101416
PAT
PATCr
452471291726343944
Growth
PAT Growth%
36.110.9-50.288.963.466.7-28.094.654.129.614.042.3
NPM
NPM%
11.010.44.87.613.016.49.415.225.726.728.730.4
EPS
EPS
1.51.70.81.62.43.92.85.48.12.612.314.0

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
666666631313131
Reserves
ReservesCr
27323337485967588290126
Current Liabilities
Current LiabilitiesCr
610141513181927212026
Non Current Liabilities
Non Current LiabilitiesCr
2678591110845
Total Liabilities
Total LiabilitiesCr
415360667392104127143146188
Current Assets
Current AssetsCr
2225253132415060756385
Non Current Assets
Non Current AssetsCr
18283535415154676883103
Total Assets
Total AssetsCr
415360667392104127143146188
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
666666631313131
Reserves
ReservesCr
27323337485967588290126
Current Liabilities
Current LiabilitiesCr
610141513181927212026
Non Current Liabilities
Non Current LiabilitiesCr
2678591110845
Total Liabilities
Total LiabilitiesCr
415360667392104127143146188
Current Assets
Current AssetsCr
2225253132415060756385
Non Current Assets
Non Current AssetsCr
18283535415154676883103
Total Assets
Total AssetsCr
415360667392104127143146188

Cash Flow

Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
26341315613232452
Investing Cash Flow
Investing Cash FlowCr
-1-10-8-2-10-19-7-13-9-22-41
Financing Cash Flow
Financing Cash FlowCr
-4441-4331-14-4-5
Net Cash Flow
Net Cash FlowCr
-2003-1-1120-35
Free Cash Flow
Free Cash FlowCr
1-5-4241561318-1742
CFO To PAT
CFO To PAT%
48.0121.6140.885.4180.0123.069.577.289.070.0134.0
CFO To EBITDA
CFO To EBITDA%
26.567.764.542.2110.282.041.150.162.452.995.4
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
26341315613232452
Investing Cash Flow
Investing Cash FlowCr
-1-10-8-2-10-19-7-13-9-22-41
Financing Cash Flow
Financing Cash FlowCr
-4441-4331-14-4-5
Net Cash Flow
Net Cash FlowCr
-2003-1-1120-35
Free Cash Flow
Free Cash FlowCr
1-5-4241561318-1742
CFO To PAT
CFO To PAT%
48.0121.6140.885.4180.0123.069.577.289.070.0134.0
CFO To EBITDA
CFO To EBITDA%
26.567.764.542.2110.282.041.150.162.452.995.4

Ratios

Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
35665842451031231924785484271,204
Price To Earnings
Price To Earnings
8.614.124.99.56.28.514.111.318.867.811.127.4
Price To Sales
Price To Sales
0.91.51.20.70.81.41.31.74.74.33.28.3
Price To Book
Price To Book
1.11.81.51.00.81.61.72.14.24.52.77.7
EV To EBITDA
EV To EBITDA
4.68.413.45.73.96.29.37.912.912.47.917.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
39.141.632.033.942.244.531.942.555.253.561.761.7
OPM
OPM%
20.018.710.415.421.224.615.923.436.735.440.342.0
NPM
NPM%
11.010.44.87.613.016.49.415.225.726.728.730.4
ROCE
ROCE%
20.117.47.713.417.721.714.322.429.735.332.632.6
ROE
ROE%
13.212.66.110.313.318.411.818.922.927.824.524.5
ROA
ROA%
10.48.83.96.79.913.18.313.318.323.120.520.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
35665842451031231924785484271,204
Price To Earnings
Price To Earnings
8.614.124.99.56.28.514.111.318.867.811.127.4
Price To Sales
Price To Sales
0.91.51.20.70.81.41.31.74.74.33.28.3
Price To Book
Price To Book
1.11.81.51.00.81.61.72.14.24.52.77.7
EV To EBITDA
EV To EBITDA
4.68.413.45.73.96.29.37.912.912.47.917.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
39.141.632.033.942.244.531.942.555.253.561.761.7
OPM
OPM%
20.018.710.415.421.224.615.923.436.735.440.342.0
NPM
NPM%
11.010.44.87.613.016.49.415.225.726.728.730.4
ROCE
ROCE%
20.117.47.713.417.721.714.322.429.735.332.632.6
ROE
ROE%
13.212.66.110.313.318.411.818.922.927.824.524.5
ROA
ROA%
10.48.83.96.79.913.18.313.318.323.120.520.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Vikram Thermo (India) is a research-driven manufacturer that makes the invisible coatings on your pills work properly. Born in 1985 and sharpened by a 2024 demerger that shed its aromatic chemicals division, the company now does one thing: it creates the specialised polymers that control how and where a medicine releases in the body. That recurring approach - in-house R&D translating polymer science into ready-to-use products, backed by hands-on technical support - explains everything that follows. # Business segments A single-engine business - a focused pharma-polymer house that sells both the raw coating ingredients and the pre-mixed, ready-to-use coating systems, all supported by an in-house application lab. ## 1. Pharma Polymers: the coatings that make pills work **The company makes the polymers that coat solid oral medicines - both as basic ingredients for formulators and as ready-to-use systems under the DRCOAT brand - and then helps customers apply them correctly.** - **Two product forms, same science** - it manufactures basic methacrylic acid and ethyl acrylate-based co-polymers (the raw coating materials) and also sells readymix coating systems under the brands DRUGCOAT, DRCOAT, APION, and AQUAPOL, giving customers a choice between building their own formulation or buying a pre-engineered solution. - **R&D is the factory's brain** - a robust in-house R&D centre staffed with pharmacists, research scientists, chemists, and chemical engineers develops the polymers, while a separate Application F&D team provides complimentary technical support to customers so the coatings perform correctly on their production lines. - **Regulatory approvals open global doors** - the company holds EXCIPACT, GMP, ISO 9001:2008, and Halal certifications, has passed audits by multiple multinational companies, and has filed US-DMFs (Drug Master Files) for its products, which means its materials are pre-qualified for use in drugs sold into regulated markets like the United States. - **Dedicated plants at two locations** - all manufacturing happens at EXCIPACT GMP-standard facilities, including one in Dhanot, Gujarat, spread over roughly 8,425 square metres, producing for both the Indian market and a steadily expanding set of export customers, with no single customer accounting for more than a tenth of revenue. - **Petrochemical roots, pharma standards** - the raw materials are petrochemical-based, so the business sits at the intersection of industrial chemistry and stringent pharmaceutical quality requirements, manufacturing to pharmacopeial GMP standards while managing energy consumption for optimum efficiency. # Group structure and partners **The company stands alone - no subsidiaries, no joint ventures - after a 2024 demerger that carved out its aromatic chemicals business into a separately listed entity, leaving Vikram Thermo as a pure-play pharma polymer company.** - **The demerger created a pure play** - the Aromatic Chemicals (Diphenyl Oxide) business was separated into Vikram Aroma Limited under an NCLT-approved scheme effective May 4, 2024, because the two businesses had different capital needs, risk profiles, and competitive landscapes, and each could scale faster on its own. - **Shareholders kept both pieces** - for every 10 shares held in Vikram Thermo, shareholders received 1 share in the new Vikram Aroma Limited, so the ownership structure remained identical across both companies, with Vikram Aroma listing on the BSE and trading from March 6, 2025. - **No subsidiaries or associates** - the company operates without any subsidiary, joint venture, or associate company, making it a straightforward, single-entity business with related-party transactions only with entities controlled by key management or their relatives, such as Vikram Ingredients Pvt Ltd and the now-separate Vikram Aroma Limited.

Documents — Vikram Thermo (India) Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/3fwo8kq27q5oy2b2l9kb47ca.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/hi80xsdnjhwzord7txm6437w.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/q3terepgiuo0e5e5wev5pxud.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/fb0nyqdvw84rc4bh9wee8lcx.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/14rrp9m66huuynhofai945tm.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/fo0dh4tkkw5hkr0xtpy9jlg5.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/yjw0sz0z5wbxqvtz3ggj2yl4.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/a365uqfkqygy6i5f8grksfmg.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/3l594pz381wl9hm5pwd86cav.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/bsxrhs224uy3jrra8rxptgtv.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/9k0y8dnpt6bwpyr9909qtetn.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/khopzi7kvm2ad9xfj1baebgp.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/ttgrdmemvi55w5uqapjnysbn.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/tx8kezpuz07m7elpp3xumf08.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/m0rq3vy6eiozojzmaw7jaw0n.pdf